Cellule staminali e Derivati

Tofacitinib (Tasocitinib) is an orally Janus kinase inhibitor. Tofacitinib is used for the treatment of rheumatoid arthritis. Cost effective and quality assured.

GS-829845 is a JAK1 inhibitor, the main component of the active metabolite of Filgotinib, which is approximately 10-fold less potent and has a longer half-life

The test principle applied in this kit is Sandwich enzyme immunoassay. The microtiter plate provided in this kit has been pre-coated with an antibody specific to Human Cys-C, and the Human Cys-C standard plate wells that pre-coated using protein-related techniques are provided separately. Standard/Sample Diluent Buffer or samples are added to the appropriate microtiter plate wells ,then added a HRP-conjugated antibody specific to Human Cys-C. After TMB substrate solution is added, only those wells that contain Human Cys-C and HRP-conjugated antibody will exhibit a change in color. The enzyme-substrate reaction is terminated by the addition of sulphuric acid solution and the color change is measured spectrophotometrically at a wavelength of 450nm ± 10nm. The concentration of Human Cys-C in the samples is then determined by comparing the OD of the samples to the standard curve.

Cerdulatinib hydrochloride is an oral tyrosine kinase inhibitor targeting JAK1/2/3, TYK2, Syk, and 19 others with IC50 < 200 nM.

Potent oral TEAD-YAP/TAZ inhibitor-2 with 3 nM EC50; exhibits anti-proliferative and antitumor effects.

<p>PRI-724 is a second-generation, selective small molecule inhibitor of the β-catenin/CBP interaction.Cost-effective and quality-assured.</p>

VT107 is a potent pan-TEAD autopalmitoylation inhibitor. VT-107 can be used in cancer therapy research.Cost-effective and quality-assured.

RO7185876 is a selective gamma secretase modulator, which can be used in the study of Alzheimer's disease.

Osunprotafib (ABBV-CLS-484) is a potent, orally bioavailable PTP1B/PTPN2 inhibitor in clinical trials for solid tumors.Cost-effective and quality-assured.

CHIR 98024: strong GSK-3α/β blocker, IC50 0.65/0.58 nM, selective over Cdc2/ERK2.

Sulindac EP Impurity C-d3 is a deuterated compound of Sulindac EP Impurity C. Sulindac EP Impurity C has a CAS number of 32004-67-4. (E/Z)-Sulindac sulfide is a potent γ-secretase modulator (GSM) that selectively reduces Aβ42 production in favor of shorter Aβ species. (E/Z)-Sulindac sulfide can be used for researching Alzheimer's disease [1].

NVP-BSK805 (BSK 805) is an ATP-competitive JAK2 inhibitor.

Livmoniplimab (ABBV-151; ARGX-115) is a humanised monoclonal antibody targeting LRRC32 (GARP)/TGFβ1, which blocks TGFβ1 release mediated by LRRC32

Nisevokitug (anti-TGF-β mAb) neutralizes TGF-β and is being studied for its ability to modulate the immunosuppressive tumor microenvironment.

Dilpacimab (ABT165) is a dual-variable antibody that targets DLL4 and VEGF pathways, showing potential in cancer research by blocking angiogenesis and Notch.

Trevogrumab is a human monoclonal antibody that inhibits myostatin (GDF8) to promote muscle growth, and is under research for treating age-related muscle loss (sarcopenia).

Tarextumab is an anti-Notch2/3 mAb, a promising candidate for breast, lung, ovarian, and pancreatic cancers.

Metelimumab (CAT-192) is a humanised monoclonal antibody targeting TGFβ1, which can be used to study diffuse systemic sclerosis (d-SSc).

Ginisortamab (UCB6114) is a fully humanized monoclonal antibody targeting Gremlin-1, IC50=8.2 nM and 9 nM against human and mouse Gremlin-1, respectively.

"Tarlatamab (AMG-757), a BiTE antibody, targets DLL3, prevalent in SCLC tumors with scant normal tissue expression, and shows promise for SCLC research."